Vigabatrin + Matching Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Addiction
Conditions
Cocaine Addiction, Cocaine Dependence
Trial Timeline
Jan 1, 2011 → Dec 1, 2012
NCT ID
NCT01281202About Vigabatrin + Matching Placebo
Vigabatrin + Matching Placebo is a phase 2/3 stage product being developed by Catalyst Pharmaceuticals for Cocaine Addiction. The current trial status is completed. This product is registered under clinical trial identifier NCT01281202. Target conditions include Cocaine Addiction, Cocaine Dependence.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01281202 | Phase 2/3 | Completed |
Competing Products
13 competing products in Cocaine Addiction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| ALKS 33-BUP + ALKS 33 + Placebo | Alkermes | Phase 1 | 30 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| CPP-115 + Placebo | Catalyst Pharmaceuticals | Phase 1 | 28 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-1300 (Injection) + Placebo (Injection) | Tonix Pharmaceuticals | Phase 2 | 44 |